Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced a clinical and corporate...
-
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that Mack Roach III, M.D.,...
-
40 percent of evaluable patients achieved survival of more than 12 months, 30 percent achieved a complete or partial tumor responseAll patients improved or maintained quality of life measures and pain...
-
Mack Roach, M.D., FASCO, University of California, San Francisco, to present data from ongoing Phase II clinical trial NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc....
-
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present...
-
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its...
-
NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present a company...
-
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, announced it has raised gross proceeds of...
-
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that...
-
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced an update of its clinical...